{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:19:27Z","timestamp":1793089167849,"version":"4.5.0"},"reference-count":202,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.intimp.2022.109130","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:48:32Z","timestamp":1660265312000},"page":"109130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":410,"special_numbering":"C","title":["Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach"],"prefix":"10.1016","volume":"111","author":[{"given":"Mansur","family":"Aliyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema Tuz","family":"Zohora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar Umar","family":"Anka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Saffarioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholamreza","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.iy.06.040188.002413","article-title":"Molecular regulation of B lymphocyte response","volume":"6","author":"Kishimoto","year":"1988","journal-title":"Annu. Rev. Immunol."},{"issue":"6092","key":"10.1016\/j.intimp.2022.109130_b0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109130_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0192-0561(92)90173-I","article-title":"IL-6 receptor and mechanism of signal transduction","volume":"14","author":"Kishimoto","year":"1992","journal-title":"Int. J. Immunopharmacol."},{"issue":"6469","key":"10.1016\/j.intimp.2022.109130_b0035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2022.109130_b0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1385\/CRIAI:28:3:177","article-title":"IL-6: from laboratory to bedside","volume":"28","author":"Kishimoto","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2022.109130_b0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.intimp.2022.109130_b0050","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109130_b0055","first-page":"79","article-title":"Regulation of IL-6 in immunity and diseases","volume":"941","author":"Tanaka","year":"2016","journal-title":"Regul. Cytokine Gene Exp. Immun. Diseases"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0060","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1084\/jem.170.6.1859","article-title":"Local production of TNF-\u03b1, IL-1 and IL-6 in meningococcal meningitis; relation to the inflammatory response","volume":"170","author":"Waage","year":"1989","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","article-title":"Plasticity and cross-talk of interleukin 6-type cytokines","volume":"23","author":"Garbers","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0070","doi-asserted-by":"crossref","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109130_b0080","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0198-8859(99)00083-X","article-title":"KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways","volume":"60","author":"Osborne","year":"1999","journal-title":"Hum. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0085","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/1096-9071(200007)61:3<332::AID-JMV8>3.0.CO;2-3","article-title":"Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion","volume":"61","author":"Mori","year":"2000","journal-title":"J. Med. Virol."},{"issue":"5293","key":"10.1016\/j.intimp.2022.109130_b0090","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1126\/science.274.5293.1739","article-title":"Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV","volume":"274","author":"Moore","year":"1996","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0095","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI2629","article-title":"The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis","volume":"102","author":"Fishman","year":"1998","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00011-015-0850-9","article-title":"Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis","volume":"64","author":"Hou","year":"2015","journal-title":"Inflamm. Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.imbio.2014.03.016","article-title":"Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation","volume":"219","author":"Poplutz","year":"2014","journal-title":"Immunobiology"},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11926-009-0051-z","article-title":"The role of toll-like receptors in rheumatoid arthritis","volume":"11","author":"Huang","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-\u03baB: a key role in inflammatory diseases","volume":"107","author":"Firestein","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(94)90333-6","article-title":"Cytokine signal transduction","volume":"76","author":"Kishimoto","year":"1994","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2015.04.029","article-title":"Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms","volume":"161","author":"Mino","year":"2015","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.intimp.2022.109130_b0135","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1073\/pnas.1307419110","article-title":"Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo","volume":"110","author":"Masuda","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0140","doi-asserted-by":"crossref","first-page":"E1214","DOI":"10.1073\/pnas.1719921115","article-title":"Regulation of inflammatory responses by dynamic subcellular localization of RNA-binding protein Arid5a","volume":"115","author":"Higa","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16","key":"10.1016\/j.intimp.2022.109130_b0145","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2174\/1381612824666180426103753","article-title":"A potential therapeutic target RNA-binding protein, Arid5a for the treatment of inflammatory disease associated with aberrant cytokine expression","volume":"24","author":"Masuda","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0150","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0155","doi-asserted-by":"crossref","first-page":"e2000080","DOI":"10.1371\/journal.pbio.2000080","article-title":"Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation","volume":"15","author":"Riethmueller","year":"2017","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/1043-4666(92)90043-Q","article-title":"Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor","volume":"4","author":"Lust","year":"1992","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH 17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"issue":"6636","key":"10.1016\/j.intimp.2022.109130_b0170","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/08977194.2012.687375","article-title":"The biology and mechanism of action of suppressor of cytokine signaling 3","volume":"30","author":"Babon","year":"2012","journal-title":"Growth Fact."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2003-04-1048","article-title":"Interleukin-6\u2013dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family\u2013independent survival pathway closely associated with Stat3 activation","volume":"103","author":"Brocke-Heidrich","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109130_b0185","doi-asserted-by":"crossref","unstructured":"T. Hirano, Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir, Proc. Japan Acad. Ser. B: Phys. Biol. Sci. 86(7) (2010) 717\u2013730. <https:\/\/doi.org\/10.2183\/pjab.86.717>.","DOI":"10.2183\/pjab.86.717"},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0190","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro-and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta-Mol. Cell Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0195","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109130_b0200","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1084\/jem.20160417","article-title":"IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21\u2013producing B helper CD8+ T cells","volume":"213","author":"Yang","year":"2016","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0205","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.4049\/jimmunol.173.6.3844","article-title":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation","volume":"173","author":"Park","year":"2004","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0215","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7090","key":"10.1016\/j.intimp.2022.109130_b0220","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0225","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0230","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0235","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/imm.12554","article-title":"Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues","volume":"147","author":"Jones","year":"2016","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0240","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4049\/jimmunol.167.6.3435","article-title":"The IL-6-soluble IL-6R\u03b1 autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin","volume":"167","author":"Marin","year":"2001","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0245","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","article-title":"Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation","volume":"14","author":"Hurst","year":"2001","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0250","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1471-4906(02)00013-3","article-title":"IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation","volume":"24","author":"Kaplanski","year":"2003","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0260","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17474086.2020.1754791","article-title":"Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures","volume":"13","author":"Barcellini","year":"2020","journal-title":"Exp. Rev. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0265","doi-asserted-by":"crossref","first-page":"19767","DOI":"10.1038\/s41598-019-56365-3","article-title":"The role of T follicular helper cells and T follicular regulatory cells in the pathogenesis of autoimmune hemolytic anemia","volume":"9","author":"Gao","year":"2019","journal-title":"Sci. Rep."},{"key":"#cr-split#-10.1016\/j.intimp.2022.109130_b0270.1","doi-asserted-by":"crossref","unstructured":"Y.S. Choi, D. Eto, J.A. Yang, C. Lao, S. Crotty, Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation, Journal of immunology (Baltimore, Md : 1950) 190","DOI":"10.4049\/jimmunol.1203032"},{"key":"#cr-split#-10.1016\/j.intimp.2022.109130_b0270.2","unstructured":"(7) (2013) 3049-3053. <https:\/\/doi.org\/10.4049\/jimmunol.1203032>."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0275","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.26452","article-title":"TLR8\/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins","volume":"97","author":"Fejtkova","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.109130_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: Clinical features and pathogenesis","author":"Jerjen","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2022.109130_b0285","doi-asserted-by":"crossref","first-page":"i195","DOI":"10.1093\/ecco-jcc\/jjab232.225","article-title":"P096 store-operated calcium entry controls innate and adaptive immune cell function in inflammatory bowel disease","volume":"16","author":"Letizia","year":"2022","journal-title":"J. Crohn's Colitis"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0290","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/jcm11040966","article-title":"Clinical relevance of liver involvement in the clinical course of systemic sclerosis","volume":"11","author":"Lorena","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.41933","article-title":"Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109130_b0300","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac074","article-title":"Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy","author":"Adler","year":"2022","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0305","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/biomedicines10020318","article-title":"Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?","volume":"10","author":"Cardoneanu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2022.109130_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01865","article-title":"Interleukin-6 and Type-I collagen production by systemic sclerosis fibroblasts are differentially regulated by interleukin-17A in the presence of transforming growth factor-beta 1","volume":"9","author":"Dufour","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0315","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0320","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1038\/s41598-022-06581-1","article-title":"Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis","volume":"12","author":"Karatas","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0325","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109130_b0330","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1007\/s10067-021-05773-w","article-title":"Evaluation of serum interleukin-6 (IL-6), IL-13, and IL-17 levels and computed tomography finding in interstitial lung disease associated with connective tissue disease patients","volume":"40","author":"Tezcan","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0335","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/injr.injr_106_17","article-title":"Serum Interleukin-6, Interleukin-17A, and transforming growth factor beta are raised in systemic sclerosis with interstitial lung disease","volume":"13","author":"Wakhlu","year":"2018","journal-title":"Ind. J. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109130_b0340","first-page":"7947596","article-title":"Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model","author":"Shieh","year":"2019","journal-title":"Mediators Inflamm."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0345","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1080\/13102818.2018.1519379","article-title":"MicroRNA-217 regulates interstitial pneumonia via IL-6","volume":"32","author":"Pan","year":"2018","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0350","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10620-020-06259-6","article-title":"Pathophysiology of gastroparesis syndromes includes anatomic and physiologic abnormalities","volume":"66","author":"Abell","year":"2021","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0355","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1038\/s41598-021-85561-3","article-title":"S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils","volume":"11","author":"Navr\u00e1tilov\u00e1","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0360","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13104-021-05860-w","article-title":"Interferon-\u03b3 induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway","volume":"14","author":"Yoshida","year":"2021","journal-title":"BMC Res. Notes"},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0365","doi-asserted-by":"crossref","first-page":"102884","DOI":"10.1016\/j.autrev.2021.102884","article-title":"Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis","volume":"20","author":"Takeuchi","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0370","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.41666","article-title":"Characterization and function of tumor necrosis factor and interleukin-6\u2013induced osteoclasts in rheumatoid arthritis","volume":"73","author":"Yokota","year":"2021","journal-title":"Arthrit. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0375","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-018-1690-0","article-title":"Enhanced IL-6\/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper\/T follicular regulatory cells in patients with rheumatoid arthritis","volume":"20","author":"Niu","year":"2018","journal-title":"Arthrit. Res. Therapy"},{"key":"10.1016\/j.intimp.2022.109130_b0380","series-title":"Textbook of Pediatric Gastroenterology, Hepatology and Nutrition: A Comprehensive Guide to Practice","first-page":"525","article-title":"Celiac disease","author":"Guandalini","year":"2022"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0385","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0198-8859(03)00027-2","article-title":"HLA types in celiac disease patients not carrying the DQA1* 05-DQB1* 02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease","volume":"64","author":"Karell","year":"2003","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.intimp.2022.109130_b0390","series-title":"Challenges and Potential Solutions in Gluten Free Product Development","first-page":"1","article-title":"Current advances in celiac disease: consequences and improvement strategies","author":"Mukhopadhyay","year":"2022"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0395","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/ijms23041973","article-title":"Inflammation is present, persistent and more sensitive to proinflammatory triggers in celiac disease enterocytes","volume":"23","author":"Porpora","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109130_b0400","doi-asserted-by":"crossref","unstructured":"K. Yasuda, Y. Takeuchi, K. Hirota (Eds.), The pathogenicity of Th17 cells in autoimmune diseases. Seminars in Immunopathology, Springer, 2019.","DOI":"10.1007\/s00281-019-00733-8"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0405","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5114\/pg.2018.79808","article-title":"The relationship between 174 G\/C and -572 G\/C of IL-6 gene polymorphisms and susceptibility of celiac disease in the Iranian population","volume":"13","author":"Barartabar","year":"2018","journal-title":"Gastroenterol. Rev.\/Przegl\u0105d Gastroenterol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5152\/tjg.2017.17092","article-title":"Interleukin-6 and interleukin-17 gene polymorphism association with celiac disease in children","volume":"28","author":"Akbulut","year":"2017","journal-title":"Turkish J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b0415","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ibd.20148","article-title":"Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance","volume":"13","author":"Mudter","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.109130_b0420","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac021","article-title":"Identification of gene expression profiles associated with an increased risk of post-operative recurrence in Crohn\u2019s disease","author":"Ngollo","year":"2022","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.intimp.2022.109130_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119433","article-title":"Regulation of IL-6\/STAT-3\/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight","volume":"276","author":"Ali","year":"2021","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0430","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12906-020-02974-9","article-title":"Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6\/STAT3 pathway","volume":"20","author":"Huangfu","year":"2020","journal-title":"BMC Complement. Med. Therap."},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b0435","first-page":"12009","article-title":"IL-6\/STAT3\/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis","volume":"8","author":"Chen","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0440","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10753-019-01171-2","article-title":"Rho kinase blockade ameliorates dss-induced ulcerative colitis in mice through dual inhibition of the NF-\u03baB and IL-6\/STAT3 pathways","volume":"43","author":"Wang","year":"2020","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07581-4","article-title":"Molecular and functional heterogeneity of IL-10-producing CD4+ T cells","volume":"9","author":"Brockmann","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2022.109130_b0450","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41385-022-00487-x","article-title":"A Notch\/STAT3-driven Blimp-1\/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in Croh\u0144s disease patients","volume":"15","author":"Ahlers","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.intimp.2022.109130_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pedn.2021.12.002","article-title":"Experiences and needs of children with siblings diagnosed with Type 1 diabetes: a mixed studies systematic review","volume":"63","author":"Chan","year":"2022","journal-title":"J. Pediatr. Nurs."},{"issue":"356","key":"10.1016\/j.intimp.2022.109130_b0460","doi-asserted-by":"crossref","first-page":"356ra119","DOI":"10.1126\/scitranslmed.aad9943","article-title":"Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression","volume":"8","author":"Hundhausen","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0465","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2016.12.74","article-title":"IL-6 and type 1 diabetes mellitus: T cell responses and increase in IL-6 receptor surface expression","volume":"5","author":"Gomes","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.intimp.2022.109130_b0470","doi-asserted-by":"crossref","first-page":"108490","DOI":"10.1016\/j.intimp.2021.108490","article-title":"Epigenetic drug ameliorated type 1 diabetes via decreased generation of Th1 and Th17 subsets and restoration of self-tolerance in CD4+ T cells","volume":"103","author":"Patel","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"21","key":"10.1016\/j.intimp.2022.109130_b0475","doi-asserted-by":"crossref","first-page":"e150074","DOI":"10.1172\/jci.insight.150074","article-title":"IL-6 receptor blockade does not slow \u03b2 cell loss in new-onset type 1 diabetes","volume":"6","author":"Greenbaum","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0480","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/jdi.13706","article-title":"Development of type 1 diabetes in a patient treated with anti-interleukin-6 receptor antibody for rheumatoid arthritis","volume":"13","author":"Kawasaki","year":"2022","journal-title":"J. Diabetes Invest."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0485","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.diabet.2020.05.005","article-title":"Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients","volume":"46","author":"Marfella","year":"2020","journal-title":"Diabetes Metab. J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0490","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0495","doi-asserted-by":"crossref","first-page":"102932","DOI":"10.1016\/j.autrev.2021.102932","article-title":"Autoimmunity in vitiligo: Therapeutic implications and opportunities","volume":"21","author":"Khaitan","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"16","key":"10.1016\/j.intimp.2022.109130_b0500","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.3390\/ijms22168820","article-title":"Metabolic comorbidities in vitiligo: a brief review and report of new data from a single-center experience","volume":"22","author":"D\u2019Arino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0505","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/ijd.IJD_300_20","article-title":"The study of serum level of interleukin-2, interleukin-6, and tumor necrosis factor-alpha in stable and progressive vitiligo patients from sina hospital in Tabriz, Iran","volume":"66","author":"Ranjkesh","year":"2021","journal-title":"Ind. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0510","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41419-021-03592-0","article-title":"A protective role for autophagy in vitiligo","volume":"12","author":"Bastonini","year":"2021","journal-title":"Cell Death Disease"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0515","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/08820139.2020.1813756","article-title":"Investigation of the role of interleukin 6 in vitiligo pathogenesis","volume":"51","author":"Singh","year":"2022","journal-title":"Immunol. Invest."},{"issue":"11","key":"10.1016\/j.intimp.2022.109130_b0520","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/biomedicines9111511","article-title":"Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Campanati","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0525","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/1547691X.2012.707700","article-title":"IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis","volume":"10","author":"Lee","year":"2013","journal-title":"J. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0530","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s42003-020-01308-2","article-title":"Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6","volume":"3","author":"Tanaka","year":"2020","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0535","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/biom10020185","article-title":"Super critical fluid extracted fatty acids from withania somnifera seeds repair psoriasis-like skin lesions and attenuate pro-inflammatory cytokines (TNF-\u03b1 and IL-6) release","volume":"10","author":"Balkrishna","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0540","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12964-018-0271-9","article-title":"MicroRNA let-7b inhibits keratinocyte differentiation by targeting IL-6 mediated ERK signaling in psoriasis","volume":"16","author":"Wu","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.intimp.2022.109130_b0545","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.2147\/JIR.S312963","article-title":"Overexpression of Lin28a aggravates psoriasis-like phenotype by regulating the proliferation and differentiation of keratinocytes","volume":"14","author":"Jang","year":"2021","journal-title":"J. Inflam. Res."},{"key":"10.1016\/j.intimp.2022.109130_b0550","doi-asserted-by":"crossref","first-page":"658980","DOI":"10.3389\/fmicb.2021.658980","article-title":"Loss of Interleukin-6 Influences Transcriptional Immune Signatures and Alters Bacterial Colonization in the Skin","volume":"12","author":"Luckett-Chastain","year":"2021","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.intimp.2022.109130_b0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01908","article-title":"S100 proteins as an important regulator of macrophage inflammation","volume":"8","author":"Xia","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0560","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5114\/ada.2018.78028","article-title":"Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis","volume":"37","author":"Pietrzak","year":"2020","journal-title":"Adv. Dermatol .Allergol"},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0565","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/idoj.idoj_306_21","article-title":"Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF \u03b1), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis","volume":"13","author":"Shah","year":"2022","journal-title":"Indian Dermatology Online Journal"},{"key":"10.1016\/j.intimp.2022.109130_b0570","doi-asserted-by":"crossref","unstructured":"Zarei, S., Eggert, J., Franqui-Dominguez, L., Carl, Y., Boria, F., Stukova, M., et al., Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico, Surgical Neurology International, 2018. 9 p 242-242. https:\/\/doi.org\/10.4103\/sni.sni_224_18.","DOI":"10.4103\/sni.sni_224_18"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0575","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12974-017-1008-1","article-title":"Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-\u03baB signaling in an IL-6-dependent manner","volume":"14","author":"Sun","year":"2017","journal-title":"J. Neuroinflam."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0580","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2022.109130_b0585","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420945135","article-title":"Recent developments in MOG-IgG associated neurological disorders","volume":"13","author":"Hegen","year":"2020","journal-title":"Therapeut. Adv. Neurol. Disord."},{"key":"10.1016\/j.intimp.2022.109130_b0590","doi-asserted-by":"crossref","first-page":"589288","DOI":"10.3389\/fneur.2020.589288","article-title":"Markedly Elevated serum level of T-helper cell 17-related cytokines\/chemokines in acute myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"11","author":"Kang","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0595","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0600","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12883-021-02198-5","article-title":"The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder","volume":"21","author":"Maghbooli","year":"2021","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0605","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11010-019-03561-4","article-title":"Role and mechanism of the Th17\/Treg cell balance in the development and progression of insulin resistance","volume":"459","author":"Tao","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.intimp.2022.109130_b0610","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00120","article-title":"IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis","volume":"14","author":"Stampanoni Bassi","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"10","key":"10.1016\/j.intimp.2022.109130_b0615","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1545968319868713","article-title":"Interleukin-6 disrupts synaptic plasticity and impairs tissue damage compensation in multiple sclerosis","volume":"33","author":"Stampanoni Bassi","year":"2019","journal-title":"Neurorehabil. Neural Repair"},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0620","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/cells8030285","article-title":"IL-6, IL-12, and IL-23 STAT-pathway genetic risk and responsiveness of lymphocytes in patients with multiple sclerosis","volume":"8","author":"von Essen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2022.109130_b0625","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2019.04.011","article-title":"IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis","volume":"332","author":"Setiadi","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109130_b0630","article-title":"Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis","author":"Omerzu","year":"2021","journal-title":"Wien. Klin. Wochenschr."},{"issue":"12","key":"10.1016\/j.intimp.2022.109130_b0635","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrrheum.2014.127","article-title":"IL-6 biology: implications for clinical targeting in rheumatic disease","volume":"10","author":"Calabrese","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0640","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.intimp.2022.109130_b0645","unstructured":"ClinicalTrials.gov [Internet]. US National Library of Medicine. 2018. [cited July 23, 2022]. <https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03235752>."},{"key":"10.1016\/j.intimp.2022.109130_b0650","unstructured":"German Clinical Trials Register. A multi-centre, exploratory trial to assess the mechanisms of molecular activity, safety and tolerability of one dose level of FE 999301 by intravenous infusions in patients with active inflammatory bowel disease (IBD). [Internet]. 2017 [cited July 23, 2022]. <http:\/\/www.drks.de\/drks_web\/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00010101>."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0655","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.intimp.2022.109130_b0660","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1L268","article-title":"Tocilizumab: an lnterleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis","volume":"42","author":"Plushner","year":"2008","journal-title":"Ann. Pharmacother."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0665","doi-asserted-by":"crossref","DOI":"10.1038\/nrd2863","article-title":"Tocilizumab","volume":"8","author":"Scheinecker","year":"2009","journal-title":"Nat. Rev. Drug Disc."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0670","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0675","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/CCM.0B013E318165BABB","article-title":"Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations","volume":"36","author":"Becker","year":"2008","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.intimp.2022.109130_b0680","series-title":"Physiology and Pathology of Cytokine: Commercial Production and Medical Use","author":"Zdravkovic","year":"2017"},{"key":"10.1016\/j.intimp.2022.109130_b0685","first-page":"100030","article-title":"The immunobiology of humanized Anti-IL6 receptor antibody: from basic research to breakthrough medicine","volume":"3","author":"Ohsugi","year":"2020","journal-title":"J. Transl. Autoimm."},{"issue":"12","key":"10.1016\/j.intimp.2022.109130_b0690","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0695","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bju.12452","article-title":"Inflammation and prostate cancer: the role of interleukin 6 (IL-6)","volume":"113","author":"Nguyen","year":"2014","journal-title":"BJU Int."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0700","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000193","article-title":"Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer","volume":"9","author":"Song","year":"2014","journal-title":"J. Thorac Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2022.109130_b0705","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0710","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejca.2008.02.047","article-title":"Systematic review of the association between circulating interleukin-6 (IL-6) and cancer","volume":"44","author":"Heikkil\u00e4","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0715","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3934\/Allergy.2021018","article-title":"The host immune responses to SARS-CoV-2 and therapeutic strategies in the treatment of COVID-19 cytokine storm","volume":"5","author":"Aliyu","year":"2021","journal-title":"AIMS Allerg. Immunol."},{"key":"10.1016\/j.intimp.2022.109130_b0720","doi-asserted-by":"crossref","first-page":"107102","DOI":"10.1016\/j.intimp.2020.107102","article-title":"Subcutaneous tocilizumab in adults with severe and critical COVID-19: a prospective open-label uncontrolled multicenter trial","volume":"89","author":"Malekzadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-05912-3","article-title":"Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India","volume":"21","author":"Gokhale","year":"2021","journal-title":"BMC Infect. Diseases"},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0730","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11684-020-0824-3","article-title":"Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial","volume":"15","author":"Wang","year":"2021","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10157-021-02126-4","article-title":"Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients","volume":"26","author":"Toda","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109130_b0740","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1136\/annrheumdis-2020-218122","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study","volume":"79","author":"Della-Torre","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0745","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.intimp.2022.109130_b0750","unstructured":"G. Gritti, F. Raimondi, D. Ripamonti, I. Riva, F. Landi, L. Alborghetti, et al., Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support, 2020."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0755","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"WHO rapid evidence appraisal for COVID-19 therapies (REACT) working group. Association between administration of il-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0760","first-page":"223","article-title":"IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy?","volume":"34","author":"Atal","year":"2020","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.intimp.2022.109130_b0765","doi-asserted-by":"crossref","DOI":"10.1159\/000522307","article-title":"Tocilizumab treatment effect on iron homeostasis in severe COVID-19 patients","author":"Guz","year":"2022","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0770","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(21)00315-5","article-title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial","volume":"4","author":"Mariette","year":"2022","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0775","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/idr14030040","article-title":"Sarilumab administration in COVID-19 patients: literature review and considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect. Disease Rep."},{"issue":"Pt A","key":"10.1016\/j.intimp.2022.109130_b0780","doi-asserted-by":"crossref","first-page":"107018","DOI":"10.1016\/j.intimp.2020.107018","article-title":"Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease","volume":"89","author":"Samaee","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0785","first-page":"767","article-title":"Interleukin-6 inhibitors in the treatment of rheumatoid arthritis","volume":"4","author":"Hennigan","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0790","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"Jones","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109130_b0795","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.782","article-title":"The soluble interleukin 6 receptor: advanced therapeutic options in inflammation","volume":"102","author":"Rose-John","year":"2017","journal-title":"Clin. Pharmacol. Therapeut."},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0800","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/eci.10.70","article-title":"Tocilizumab for the treatment of rheumatoid arthritis","volume":"6","author":"Tanaka","year":"2010","journal-title":"Exp. Rev. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0805","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The role of IL-6 in host defence against infections: immunobiology and clinical implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2040622312466908","article-title":"Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy","volume":"4","author":"Kaneko","year":"2013","journal-title":"Therapeut. Adv. Chronic Disease"},{"key":"10.1016\/j.intimp.2022.109130_b0815","first-page":"Cd008331","article-title":"Tocilizumab for rheumatoid arthritis","volume":"7","author":"Singh","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0820","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00003495-200969050-00007","article-title":"Tocilizumab: a review of its use in the management of rheumatoid arthritis","volume":"69","author":"Oldfield","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2022.109130_b0825","doi-asserted-by":"crossref","unstructured":"A. Venkiteshwaran, Tocilizumab, mAbs 1(5) (2009) 432-438. <https:\/\/doi.org\/10.4161\/mabs.1.5.9497>.","DOI":"10.4161\/mabs.1.5.9497"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0830","first-page":"402","article-title":"Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis","volume":"16","author":"Schafer","year":"2010","journal-title":"J. Manage. Care Pharm."},{"key":"10.1016\/j.intimp.2022.109130_b0835","doi-asserted-by":"crossref","unstructured":"D.V. Parums, Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19, Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res. 27 (2021) e933973 <https:\/\/doi.org\/10.12659\/msm.933973>.","DOI":"10.12659\/MSM.933973"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0840","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1759720X12455960","article-title":"Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis","volume":"4","author":"Yokota","year":"2012","journal-title":"Therapeut. Adv. Musculoskel. Disease"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0845","first-page":"1","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthrit. Res. Therap."},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b0850","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2022.109130_b0855","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0860","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-018-0737-1","article-title":"Recent advances in giant cell arteritis","volume":"20","author":"Guevara","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2022.109130_b0865","series-title":"Actemra\u00ae(tocilizumab) injection for intravenous infusion","author":"Genentech","year":"2012"},{"key":"10.1016\/j.intimp.2022.109130_b0870","series-title":"SAT0270 Tocilizumab in refractory takayasu arteritis. Open-label national multicenter study of 53 patients of clinical practice","author":"Prieto-Pena","year":"2020"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0875","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14397595.2020.1724671","article-title":"Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: a systematic review of randomized controlled trials","volume":"31","author":"Singh","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2022.109130_b0880","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Ann. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.109130_b0885","unstructured":"COVID-19 treatment guidelines. Interleukin-6 inhibitors [Internet]. NIH. 2021 [cited June 09, 2022]. <https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/interleukin-6-inhibitors\/#:\u223c:text=The%20Panel%20recommends%20against%20the,a%20clinical%20trial%20(BIII)>."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0890","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40121-020-00373-8","article-title":"Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study","volume":"10","author":"Ruiz-Antor\u00e1n","year":"2021","journal-title":"Infect. Diseases Therapy"},{"issue":"7","key":"10.1016\/j.intimp.2022.109130_b0895","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-015-0453-1","article-title":"Clinical development of siltuximab","volume":"17","author":"Davis","year":"2015","journal-title":"Curr. Oncol. Rep."},{"issue":"10","key":"10.1016\/j.intimp.2022.109130_b0900","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","article-title":"Siltuximab: first global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0905","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: a review in moderate to severe rheumatoid arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0910","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40265-017-0724-2","article-title":"Sarilumab: first global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b0915","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40259-018-0320-3","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what's the difference?","volume":"32","author":"Avci","year":"2018","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0920","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in the management of non-infectious uveitis and beyond","volume":"9","author":"Karkhur","year":"2019","journal-title":"J. Ophthal. Inflam. Infect"},{"issue":"12","key":"10.1016\/j.intimp.2022.109130_b0925","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/carcin\/bgab102","article-title":"Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3\/AUF1 pathway","volume":"42","author":"Al-Jomah","year":"2021","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0930","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mc.23270","article-title":"Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells","volume":"60","author":"Alraouji","year":"2021","journal-title":"Mol. Carcinog."},{"issue":"9","key":"10.1016\/j.intimp.2022.109130_b0935","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mc.23234","article-title":"Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer","volume":"59","author":"Alraouji","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0940","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-021-00371-0","article-title":"Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6","volume":"8","author":"Chung","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b0945","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/cells10081928","article-title":"The P2X7 receptor stimulates IL-6 release from pancreatic stellate cells and tocilizumab prevents activation of STAT3 in pancreatic cancer cells","volume":"10","author":"Magni","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2022.109130_b0950","doi-asserted-by":"crossref","unstructured":"K. Yamaguchi E. Fujii S. Mitsunaga N. Sawada M. Ikeda T. Fujitomo et al. Abstract 6145: Increased PD-L1 expression levels were observed on both tumor cells and macrophages by tocilizumab plus gemcitabine\/nab-paclitaxel treatment in gemcitabine\/nab-paclitaxel-refractory metastatic pancreatic cancer patients Cancer Res. 82 12_Supplement 2022 6145 6145 https:\/\/doi.org\/10.1158\/1538-7445.am2022-6145.","DOI":"10.1158\/1538-7445.AM2022-6145"},{"issue":"2","key":"10.1016\/j.intimp.2022.109130_b0955","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3892\/or.2022.8349","article-title":"Dual STAT-3 and IL-6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL-6\/IL-6R\/STAT-3 axis","volume":"48","author":"M\u00e9ndez-Clemente","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2022.109130_b0960","first-page":"5532258","article-title":"Tocilizumab controls paraneoplastic inflammatory syndrome but does not suppress tumor growth of angiomatoid fibrous histiocytoma","author":"Sabe","year":"2021","journal-title":"Case Rep. Oncol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109130_b0965","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0970","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.2935","article-title":"Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma","volume":"225","author":"Shinriki","year":"2011","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109130_b0975","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2015.3019","article-title":"Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells","volume":"9","author":"Kim","year":"2015","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2022.109130_b0980","first-page":"310","article-title":"Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells","volume":"41","author":"Yi","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2022.109130_b0985","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","article-title":"Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer","volume":"16","author":"Guo","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109130_b0990","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","article-title":"A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Hudes","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"13","key":"10.1016\/j.intimp.2022.109130_b0995","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/pros.21362","article-title":"The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study","volume":"71","author":"Karkera","year":"2011","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.intimp.2022.109130_b1000","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-05-3447","article-title":"Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice","volume":"66","author":"Wallner","year":"2006","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2022.109130_b1005","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Rossi","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922006142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:55:45Z","timestamp":1761587745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922006142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":202,"alternative-id":["S1567576922006142"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109130","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109130"}}